Luxturna is a gene therapy that uses a harmless virus to replace a mutated RPE-65 gene with a normal copy in the retinal cells. The normal copy of the gene will allow for the production of necessary proteins and gradually preserve and improve visual function.
The new treatment will be used for patients with Leber congenital amaurosis, which is blindness caused by mutations that deteriorate the retinal cells and cause a progressive loss of vision. LCA is the leading cause of inherited blindness in children, and mutations in both copies of the RPE-65 gene can make children start to lose their vision at 5 years old.
Dean McGee partnered with OU Health Pharmacy and the OU Outpatient Surgery Center to offer the new treatment, reducing the distance LCA patients previously had to travel to receive this treatment.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.